Advances in ocular corticosteroid therapy.
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D002386:Cataract / Q000139:chemically induced; D004338:Drug Combinations; D005128:Eye Diseases / Q000139:chemically induced / Q000188:drug therapy*; D005148:Facial Dermatoses / Q000188:drug therapy; D005469:Fluorometholone / Q000627:therapeutic use; D005901:Glaucoma / Q000139:chemically induced; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy; D007249:Inflammation / Q000188:drug therapy; D007634:Keratitis / Q000139:chemically induced; D007635:Keratitis, Dendritic / Q000139:chemically induced; D009181:Mycoses / Q000139:chemically induced; D011282:Pregnenediones / Q000627:therapeutic use; D011559:Pseudotumor Cerebri / Q000139:chemically induced; D011817:Rabbits; D014221:Triamcinolone / Q000009:adverse effects
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D011282:Pregnenediones; D014221:Triamcinolone; D005469:Fluorometholone